TABLE 1.

Population enrolled by each study that returned negative results

Site	Population
1	Adults without clinical indication who had participated in prior pharmacogenomic sequencing
2	Adolescents without clinical indication
3	Three cohorts: Adults without clinical indication who were members of the biobank Asian adults without clinical indication who were members of the biobank Adults with history of colorectal cancer and or familial polyposis who were members of the biobank
4	Latino or Ashkenazi Jewish adults without clinical indication
5	Adults who were outpatients of nephrology, liver, and oncology clinics
6	Adults without clinical indication who were participants of eMERGE II pharmacogenomic study
7	Adults with hyperlipidemia or colon polyps
8	Latino adults with hyperlipidemia or colon polyps
9	Adults with and without a family history for cancer, hyperlipidemia, and heart arrhythmia
10	African American patients who had breast, lung, colon, or prostate cancer, or were at-risk for cancer per NCCN guidelines for these four cancers